Overview

Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients

Status:
Recruiting
Trial end date:
2023-08-04
Target enrollment:
0
Participant gender:
All
Summary
Prospective phase IV interventional open label randomized controlled trial to assess safety and efficacy of glutamine in preventing vaso-occlusive crisis (VOC) episodes in sickle cell pediatrics and adolescents' patients
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ain Shams University
Criteria
Inclusion Criteria:

Children and adolescents diagnosed with sickle cell disease by haemoglobin electrophoresis
and had at least two pain crises (no upper limit) documented during the previous year; a
pain crisis is defined as pain leading to treatment with a parenteral administered narcotic
or ketolac in an emergency department (ED) (or outpatient treatment centre) or during
hospitalization.

Patients receiving hydroxyurea at a fixed dose for at least 3 months before screening.

Exclusion Criteria:

Patients with sickle cell trait and other hemoglobinopathy.

-